Posted by AGORACOM
at 11:53 AM on Monday, December 6th, 2021
Shareholders & friends,
Off the back of announcing our deals with Times Internet and Polygon ($MATIC), I wanted to end the week with a personal note. This week was a watershed moment for GameOn. A moment when a small, relatively unknown CA$20 million market cap company became backed by India’s largest media conglomerate and a leading blockchain with a US$22 billion market cap. This is strong validation of the mission, products and team that fuel our business each day.
While many don’t know who we are yet, that’s now shifting. Just yesterday, we were written up by VentureBeat, a tech news leader that receives 12 million monthly views and is regularly read by Mark Zuckerberg. I was also recently featured in Forbes. Both customers and investors are being awoken by the noise we’re making, and they’re starting to take note.
While the market has been choppy, we’ve quietly had our heads down building and closing deals. 2022 is set up to be the year of scaling customers and revenue. If you’ve followed us since listing, you’ll know we execute on what we say we will. We expect the next 12-24 months to be no different. The first inning is over. Batter up for the second, now with the likes of Times Internet and Polygon on-deck.
Look out for a more detailed corporate update next week. In the meantime, thank you for the ongoing support. Have a great weekend!
Cheers, Matt
Polygon Studios Invests in GameOn, Strategically Partners to Bring NFT Games to the MassesGameOn Secures Up to US$6 Million in Strategic Investment from India’s Brand Capital International
Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice
Total revenue of $1,857,750, +113% when compared to same period last year
Total working capital of $6,834,011 to fund operations
“Q1 was a strong start to fiscal year 2022, driven by the addition of another clinic to our network and increased patient demand for our comprehensive range of innovative mental health treatments,” said Yaron Conforti, Novamind’s CEO and Director. “We continue to make progress on our national clinic expansion, most recently with a letter of intent to acquire two locations in Arizona. Our clinical research business has been actively building an exciting pipeline of contracts with leading drug developers.”
“Novamind operates best-in-class psychiatry clinics and clinical research sites, with a proven ability to replicate our clinic model in the U.S. Our agreement with Bienstar is an exciting opportunity to export our clinical expertise and capabilities into international markets,” said Yaron Conforti, Novamind CEO and Director. “Partnering with local operators allows us to disseminate Novamind’s best practices and SOPs globally, with minimal investment and managed risk, ultimately expanding access to psychedelic medicine and innovative mental healthcare on a global scale.”
Novamind’s CEO and Director, Yaron Conforti, will join the Psychedelics Assisted Psychotherapy panel discussion from 1:30 PM to 2:15 PM EST. Mr. Conforti will also deliver a corporate presentation to update investors on recent milestones and progress towards the global expansion of Novamind’s psychedelic clinics and research sites.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the concept of the “middle way” and the need for balance in an increasingly polarized world.
In a piece for The Guardian, psychedelic pioneer Rick Doblin explains how psychedelics can change humanity for the better. “We envision a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.”
The work to destigmatize psychedelics has been long and arduous. Just ask Rick Doblin. He’s devoted his life to it. But as more and more research comes out, more and more people are changing their opinion on the once villainized substances. “Public attitudes around psychedelics are shifting: A recent Nanos Research survey, commissioned by the Canadian Psychedelic Association, found that 82 per cent of Canadians are in favour of psilocybin-assisted therapy in end-of-life illness, while 78 per cent of those polled support legalizing it to improve the quality of life for palliative and end-of-life patients.”
Posted by AGORACOM-JC
at 6:23 PM on Wednesday, December 1st, 2021
As the name implies, ImagineAR (IP:CSE / IPNFF:OTCQB) is an Augmented Reality Company … but they’re not just any AR company. Imagine enables businesses to create their own mobile phone AR campaigns with no programming or technology experience.
Why is that important? Ask Apple CEO Tim Cook who stated
“AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smartphone”
For those of you that are just discovering Augmented Reality, “AR” is essentially a technology that lays digital images and graphics over the real world, typically by looking through your cell phone or special glasses. If you think it sounds like a gimmick, it isn’t. AR will create an entirely new revenue stream for businesses, organizations and sports teams that will boggle the mind in the next 3 years.
ImagineAR provides small-cap investors with an opportunity to participate in the growth of this mega-market in the making …. and IP delivered record revenues in the first 9 months of the year with a 385% increase over last year to prove it, thanks to deals and announcements as follows:
Tier-1 Clients
Shoppers Drug Mart
NFL Alumni,
2 biggest soccer teams in Spain – Valencia / Real Sociedad
Club Atletico Mineiro (Brazil)
Grubhub Sound Bites: Megan Thee Stallion, Noah Cyrus
Hype Sports Global Accelerator Program where it was selected by 18 various sports teams, leagues, and broadcasters including
SPORTS – Vegas Knights, Philadelphia Phillies,
ESPORTS – SK Gaming; FC Koln
MEDIA – Sinclair Broadcasting, Rogers Communications,
What did Alen Paul Silverrstieen, CEO and President of Imagine AR have to say;
“To be selected as a 2021 STA Startup Category Stage Winner for Fan Engagement is truly an honor and further positions our company as one of the up-and-coming global sports tech leaders,” said “This STA selection can open up new sales and partnership opportunities for ImagineAR as well throughout the world. We are excited to compete against other global winners for the overall 2021 Startup of the Year Award in the near future.”
Using the FameDays TM mobile app for both IOS and Android, fans can enjoy birthday, holiday, superfan hologram video messages right in their home and record their own videos and pics with the virtual star as if they are standing right next to them in real life and share in social media. Premiere hologram stars are expected to include NFL & MLB Superstars, Reality TV Stars, Pro Wrestlers and new celebrity holograms to be added regularly.
Is this worth getting excited about?
Did you know….
Sit back, relax and watch this powerful interview with Alen Paul Silverrstieen, CEO and President of Imagine AR.
Posted by AGORACOM-JC
at 4:37 PM on Tuesday, November 30th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
The US patent covers the PUREVAP™ QRR innovative process, which permits the one-step transformation of quartz (SiO 2 ) into high purity silicon metal (from 99.5% to 99.99% Si) at reduced costs, energy input, and carbon footprint. This game-changing advantage means that the PUREVAP™ QRR process not only produces a higher purity silicon material than traditional processes, but it does not require the extremely pure feedstock needed by conventional processes. In fact, the process only requires 4.5 MT of raw material to make 1 MT of Silicon, versus the 6 MT required by conventional processes, a 25% reduction which potentially allows a 20% cash cost advantage versus the lowest cost traditional Silicon producer . Furthermore, as part of our ongoing strategy of protecting and strengthening the PUREVAP™ Intellectual Property Portfolio, a second patent application, focusing on a new and novel process was filed in 2019 and is presently advancing through the process.
Bernard Tourillon, President and CEO of HPQ commented,
“HPQ has been at the forefront of Low-Cost Green Silicon innovation developments since 2015, and getting this U.S. patent approval, combined with the ongoing commissioning of the GEN3 PUREVAP™ QRR pilot plant , has occurred at an opportune time, as demand continues to rise and bottlenecks we had foreseen are now occurring in the silicon supply chain. With ESG principles playing an active role in materials sourcing, the world is more aware of the difficulty of securing the ESG compliant Silicon needed to meet its renewable energy goals. The reality of chronic underinvestment in new technologies combined with the offshoring of Silicon production capacity, has created a massive opportunity for HPQ and its PUREVAP™ QRR patented process, as we are the only company to bring to market a new process to make Silicon that is perfectly suited to the new demands and realities of the Silicon market
Watch this great interview with $HPQ CEO Bernard Tourillon.
Steven McAuley, Chairman and CEO of Empower commented:
“This quarter marked the start of a new chapter for the Company and the Empower team. We launched The Medi-Collective brand and clinics, expanded Kai Labs’ facilities and completed the acquisition of MediSure. Each of these milestones is an intrinsic aspect of our strategic growth vision.“
Key Q3-2021 Highlights:
Revenue from continuing operations of $405,707 compared to $85,960 in Q3 2020, representing 372% year-over-year growth.
Revenue from continuing operations of $3,226,335 for nine months YTD 2021 compared to $222,690 for nine months YTD 2020, representing 1,349% year over year growth.
What does CEO Steven McAuley think of these results?
“With positive year-over-year growth coming out of this quarter, we will maximize our fully operational divisions’ capabilities and reach across Canada and the U.S. I’m encouraged by our partnerships and acquisitions progress into Q4 2021 and look forward to the coming months.”
Sit back, relax and watch this powerful interview.
We are pleased to launch our new logo and announce that the Company will unite its subsidiaries and brands under a single Novamind brand.
Novamind is investing in a revitalized and unified brand following a year of significant growth including expansion into new states, launching new clinics and research sites and bringing to market several innovative mental health care offerings.
Novamind’s new logo is now live on its corporate website and social media platforms. The logo integrates and flows across all digital and physical properties, and represents Novamind’s core beliefs in hope, healing and transformation. The open doorway at the centre of the logo, working in conjunction with the radiating lines, is an invitation towards an improved way of life—one where taking care of mental health is a priority.
The logo reveal kicks off the multi-phase rebrand of the Company’s network of clinics and research sites, expected to be complete in 2022. The Company is also improving its website to scale alongside its growth strategy and better serve diverse audiences with enhanced content and tools. Taking inspiration from the revitalized logo, the website will provide an accessible digital entry point to Novamind’s world-class care and clinical research offerings.
Yaron Conforti, CEO and Director, commented: “The new logo, rebrand and website reflects our rapid evolution over the last year. It’s an exciting opportunity to unify our current and future assets under one unique identity that will become a trusted and recognized name for innovative mental healthcare in communities across the U.S.”
In this episode of the Psychedelic Therapy Frontiers podcast, Hannah Cross is back and joinsDr. Steve Thayer and Dr. Reid Robison to explore psycho-spiritual emergencies. Hannah is a licensed clinical social worker, therapist, reiki master and yoga teacher.
Could MDMA-assisted therapy be a treatment for alcohol use disorder? A new study says psychotherapy under the influence of the drug MDMA could help patients process the traumatic experiences that are often the root cause of this condition. Psychedelics have long been considered in the treatment of alcohol use disorder, with scientists in the ‘60s hypothesizing that it might. Click the link above to learn more about MDMA and alcohol use disorder. Learn more about LSD and alcohol use disorder here.
Virtual reality could be the next great digital frontier. And thinking has already begun for how it can advance the mental health revolution we are currently in. “The use of VR in medical settings to provide emotional care is not a new concept. Over the past several years VR has been employed with greater frequency and effectiveness in ways large and small. Recently, the staff at a hospital in Long Beach, California, used virtual reality tech in a simple yet valuable context, distracting young patients during medical procedures like removing a cast.”
Your genetics may hold some clues as to how psychedelics might affect you. But the test isn’t perfect and results should be taken with a grain of salt: “The test covers five different DNA markers for psychedelic sensitivity, metabolism, and mental health risk. However, some of the conclusions drawn by HaluGen are oversimplified or based on outdated science, experts told VICE.”
Researchers from the Yale Department of Psychiatry were awarded a US$2 million grant for a first-of-its-kind clinical trial. “Holmes and Sanacora will compare the efficacy of ketamine (six infusions administered intravenously over three weeks) to placebo in 50 individuals with Parkinson’s disease and depression. Using cutting-edge brain imaging they will also study the mechanistic effects of ketamine on synaptic connections and functional networks in the brain.” In a similar vein, we recently launched the Psychedelic Palliative Care by Novamind program earlier this fall. It’s a program that supports the mental health of adults coping with serious or chronic physical illness such as cancer, heart disease, Parkinson’s or pain conditions. Learn more here.
Posted by AGORACOM
at 3:09 PM on Tuesday, October 26th, 2021
AI/ML Innovations is capitalizing on the burgeoning areas of artificial intelligence (AI), cloud computing and machine learning (ML), with an initial focus on emerging companies in the digital healthcare space.
Its key subsidiary, Health Gauge, is a leading digital health solutions provider that’s disrupting the traditional healthcare industry by providing AI innovations and services that improve health outcomes, while at the same time reducing costs and stresses on the overburdened healthcare infrastructure.
Its patent-pending solution is a bespoke personal health monitoring and management system, combining the latest wearable health monitors with sophisticated software tools.
Health Gauge provides for a secure and trusted means for clients to engage clinical resources and health coaching as a regular part of their care process and ongoing health management. Its robust, real-time data capture capability provides fast feedback, resulting in better recovery outcomes and healthy living objectives through the ability to make immediate and better health choices.
In addition to Health Gauge, AI/ML also has a strategic partner in Tech2Heal, a France-based global provider of proprietary digital mental health and wellness products.
In late September, AI/ML announced that it had completed its transaction to acquire a significant interest in Tech2Heal (dba Tech2Health), and that Tech2Heal was readying its remote patient monitoring platform for deployment.
Now, AI/ML Innovations & Tech2Heal’s AI Rx joint venture is preparing for imminent launch into the U.S. market, with a basket of wellness and health-tech products and services designed to improve an individual’s mental health and well-being, and utilizing a unique blend of proprietary digital assets, remote live counselling, and a physical wellness center.
We caught up with Tim Daniels, AI/ML’s Executive Chairman, to discuss the firm’s progress…
In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind.
Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.
Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.
Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.
We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.
“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”
Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.
“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”
Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.
Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.
Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”
Posted by AGORACOM-JC
at 10:01 AM on Wednesday, October 6th, 2021
12 months ago investors couldn’t be blamed if they found it hard to grasp the genius and foresight of Liquid Avatar $LQID $LQAVF ….. the easiest way to describe the company was as a blockchain platform allowing people to manage & profit from their digital identity, which became a real need once global laws started being enacted to prevent the likes of Facebook from every abusing our private information again.
Moreover, the platform also provides both businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).
It sounded great … and definitely sounded like something you could see starting to happen 3-4 years into the future … but then the signs started showing up that painted an accelerating picture that would put LQID at the forefront of digital identity.
1. In March of this year, Google validated the $LQID business model with this stunning announcement:
Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
“Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,
What is the potential outcome of this major shift by Google?
“Google’s decision could upend the ad industry, which has relied on these types of tracking tools”
With this news, the data privacy and monetization game is underway and LQID sitting in a great position within the industry and the dominant position within the small cap world.
BUT THAT’S NOT ALL
2. In May of this year, The Ontario government released its digital identity strategy outlining ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments.
Then came the news all Liquid Avatar investors were waiting for:
the introduction of a new government-issued digital ID that lets people prove who they are both online and in person.
These 2 announcements out of Google and the Ontario Government officially put both business and government in the digital identity and credentials game. There is no looking back.
ENTER LIQUID AVATAR – WORKING WITH ONTARIO GOVERNMENT
Enter $LQID whose Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem, including the Holder, Issuer and Verifier, using state-of-the-art blockchain and open standards technologies . More than just a good idea, $LQID issued a press release announcing the following:
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation”
AND
“Liquid Avatar Technologies has been a part of the ongoing consultations around the province’s plan to introduce a digital identification credential by the end of 2021”
ENTER LIQUID AVATAR – OUT OF DEVELOPMENT AND INTO COMMERCIALIZATION WITH 8,000 CONVENIENCE STORES
This morning $LQID released major news on the commercialization side whose title speaks for itself:
According to CEO Lucatch, this announcement represents a major inflection point as it signals a shift from development to commercialization, with many more potential deals in discussion.
LQID IS THE LEADING SMALL CAP COMPANY IN MASSIVE PARADIGM SHIFT TOWARD DIGITAL IDENTITY, PRIVACY AND MONETIZATION
Make no mistake about it. This is a simply massive paradigm shift and $LQID isn’t going to tackle this on its own. The Company is a voting and steering committee member of the Trust over IP Foundation, founding and steering committee member of Cardea, a Linux Foundation Public Health project, member of the Good Health Pass collaborative, ID2020, DIACC, The Linux Foundation and a founding member of the Lumedic Exchange.
Suddenly it is getting easy to see the genius of Liquid Avatar.
Watch this great interview with CEO David Lucatch.
Posted by AGORACOM
at 4:55 PM on Thursday, September 30th, 2021
MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.
For the purposes of introducing you to Mountain Valley MD (MVMD), we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.
BUT
One thing we don’t know or understand about vaccinations is that they are only as good as:
1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;
2. The delivery system into your body (i.e. injection)
If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good. This is where MVMD comes in. They don’t make the vaccines, drugs or pharmaceuticals.
What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good. By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.
A “magic bullet” is of little use without a “magic gun” – Mountain Valley MD Is The Magic Gun.
Check out these Trials & Research MVMD is accomplishing with their Vaccine technology to improve our lives:
* Expanding Oncology Work for BreastCancer using Quicksol™ technology applications
* Farm Animal Trials Using Solubilized Ivermectin
* Discovering Immediate Demand for Generic Ivermectin Uses
The latest news Involves utilizing their vaccine technology to address & develop products for the Medical Sleep Market in the U.S. strictly using cannibinoids.
Sit back and enjoy the great interview with President & CEO Dennis Hancock as he explains the developing relationship with Red White & Bloom to create products for the US sleep market.
